Jefferies Raises Medivation (MDVN) Price Target to $95

Jefferies boosted its price target on Medivation (NASDAQ: MDVN) from $62 to $95 while reiterating their Buy rating following "robust" AFFIRM data on all fronts.

The firm comments, "MDVN released further details from the Ph 3 AFFIRM trial evaluating MDV3100 in castrate-resistant prostate cancer (CRPC) which will be presented at ASCO-GU on Feb 2. While the interim top-line data were release in early Nov, the additional dataset reveals a stellar efficacy/safety profile."

For an analyst ratings summary and ratings history on Medivation click here. For more ratings news on Medivation click here.

Shares of Medivation closed at $55.41 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• HSBC Downgrades Feng Tay Enterprises (9910:TT) to Hold
• Comerica (CMA) PT Raised to $54 at Piper Sandler
• Intuitive Surgical (ISRG) PT Raised to $435 at Piper Sandler